NEW YORK (TheStreet) -- Shares of Endo (ENDP) were down 16.72% to $15.13 on heavy trading volume late Thursday afternoon as the Department of Justice could file charges in an investigation of roughly a dozen generic drug makers by the end of this year, Bloomberg reports.
The probe is looking at whether companies colluded on drug pricing, according to Bloomberg.
Companies such as Mylan (MYL) and Teva (TEVA) are said to have disclosed subpoenas. Shares of Mylan and Teva were trading sharply lower this afternoon as well.
Drug companies have been rebuked in recent months for drastically raising the prices of certain treatments.
About 10.97 million shares of Endo have been traded so far today, well above the company's average trading volume of roughly 5.60 million shares a day.
Separately, TheStreet Ratings team rates the stock as a "sell" with a ratings score of D.
Endo's weaknesses include its disappointing return on equity, generally disappointing historical performance in the stock itself and generally high debt management risk.
You can view the full analysis from the report here: ENDP
TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author.